| 摘要 |
PROBLEM TO BE SOLVED: To provide a medical use of a recombinant Ganoderma lucidum immunoregulatory protein (rLZ-8) for an anti-tumor, inhibition of increased leukocyte count and immunological rejection, and the like.SOLUTION: The protein gene sequence is derived from Ganoderma lucidum, and is re-designed to be more suitable for the recombinant expression using the eukaryotic expression system of Pichia pastoris. The crystal structure (tertiary and quaternary structure) of rLZ-8 is acquired by X-ray diffraction. According to the invention, any protein molecule having the structure is used as an anti-tumor drug or a drug which increases a leukocyte count, or an immune inhibitor. The pharmaceutical composition can be also used when indications associated with the increased leukocyte count are various tumors, various neutrophilic granulocytopenia, leukopenia by chemical intoxication or exposure to radiation, leukopenia accompanying infectious diseases due to bacteria, viruses, or mycoplasma, or leukopenia by medication. |
